Caseware UK (AP4) 2023.0.135 2023.0.135 2024-04-302024-04-30true2023-05-01falseNo description of principal activity22trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 06980862 2023-05-01 2024-04-30 06980862 2022-05-01 2023-04-30 06980862 2024-04-30 06980862 2023-04-30 06980862 c:Director2 2023-05-01 2024-04-30 06980862 d:FurnitureFittings 2023-05-01 2024-04-30 06980862 d:FurnitureFittings 2024-04-30 06980862 d:FurnitureFittings 2023-04-30 06980862 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 06980862 d:ComputerEquipment 2023-05-01 2024-04-30 06980862 d:ComputerEquipment 2024-04-30 06980862 d:ComputerEquipment 2023-04-30 06980862 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 06980862 d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 06980862 d:CurrentFinancialInstruments 2024-04-30 06980862 d:CurrentFinancialInstruments 2023-04-30 06980862 d:CurrentFinancialInstruments d:WithinOneYear 2024-04-30 06980862 d:CurrentFinancialInstruments d:WithinOneYear 2023-04-30 06980862 d:ShareCapital 2024-04-30 06980862 d:ShareCapital 2023-04-30 06980862 d:RetainedEarningsAccumulatedLosses 2024-04-30 06980862 d:RetainedEarningsAccumulatedLosses 2023-04-30 06980862 c:OrdinaryShareClass1 2023-05-01 2024-04-30 06980862 c:OrdinaryShareClass1 2024-04-30 06980862 c:OrdinaryShareClass1 2023-04-30 06980862 c:FRS102 2023-05-01 2024-04-30 06980862 c:AuditExempt-NoAccountantsReport 2023-05-01 2024-04-30 06980862 c:FullAccounts 2023-05-01 2024-04-30 06980862 c:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 06980862 e:PoundSterling 2023-05-01 2024-04-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 06980862









PHARMAWISE LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 APRIL 2024

 
PHARMAWISE LTD
REGISTERED NUMBER: 06980862

STATEMENT OF FINANCIAL POSITION
AS AT 30 APRIL 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
14,499
4,393

  
14,499
4,393

Current assets
  

Debtors: amounts falling due within one year
 5 
68,517
84,974

Cash at bank and in hand
 6 
263
425,338

  
68,780
510,312

Creditors: amounts falling due within one year
 7 
(33,407)
(58,291)

Net current assets
  
 
 
35,373
 
 
452,021

Total assets less current liabilities
  
49,872
456,414

  

Net assets
  
49,872
456,414


Capital and reserves
  

Called up share capital 
 8 
100
100

Profit and loss account
  
49,772
456,314

  
49,872
456,414


Page 1

 
PHARMAWISE LTD
REGISTERED NUMBER: 06980862
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 30 APRIL 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




P Mendelsohn
Director

Date: 13 January 2025

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
PHARMAWISE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

1.


General information

Pharmawise Ltd is a private company limited by shares and incorporated in England and Wales.  Its registered number is 06980862 and its registered address is 101 New Cavendish Street, 1st Floor South London, United Kingdom, W1W 6XH.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.4

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

Page 3

 
PHARMAWISE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.Accounting policies (continued)

 
2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Fixtures and fittings
-
25%
Straight line
Computer equipment
-
33%
Striaght line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 4

 
PHARMAWISE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.Accounting policies (continued)

 
2.10

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2023 - 2).


4.


Tangible fixed assets





Fixtures and fittings
Computer equipment
Total

£
£
£



Cost or valuation


At 1 May 2023
12,626
17,742
30,368


Additions
9,930
2,806
12,736



At 30 April 2024

22,556
20,548
43,104



Depreciation


At 1 May 2023
12,626
13,349
25,975


Charge for the year on owned assets
207
2,423
2,630



At 30 April 2024

12,833
15,772
28,605



Net book value



At 30 April 2024
9,723
4,776
14,499



At 30 April 2023
-
4,393
4,393

Page 5

 
PHARMAWISE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

5.


Debtors

2024
2023
£
£


Trade debtors
46,725
76,539

Other debtors
21,792
8,435

68,517
84,974



6.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
263
425,338

Less: bank overdrafts
(14,293)
-

(14,030)
425,338



7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Bank overdrafts
14,293
-

Trade creditors
9,148
128

Amounts owed to group undertakings
540
540

Corporation tax
-
48,647

Other taxation and social security
1,490
1,373

Other creditors
614
294

Accruals and deferred income
7,322
7,309

33,407
58,291



8.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



100 (2023 - 100) Ordinary Shares of £1.00000 each
100
100


 
Page 6